Peptide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Equipment, Reagents and Consumables, Others), By Technology {Solid-Phase Peptide Synthesis (SPPS), Solution-Phase Synthesis (SPS), Liquid-Phase Peptide Synthesis (LPPS)}, By Application (Therapeutics, Diagnosis, Research), By End-User (Pharmaceutical and Biotechnology Companies, Contract Manufacturing Organization (CMO), Academic and Research Institutes), By Region and Competition, 2020-2030F

Market Overview

Global Peptide Synthesis Market has valued at USD 524.26 Million in 2024 and is expected to reach USD 778.45 Million by 2030 with a CAGR of 6.81% during the forecast period. Peptides are synthesized through the coupling of the carboxyl group of one amino acid with the amino group of another amino acid molecule. To avoid unintended reactions, protective measures are commonly employed. Chemical peptide synthesis typically initiates from the carboxyl end of the peptide, progressing towards the amino terminus, which is contrary to the direction of protein biosynthesis. Peptides serve as highly effective and selective signaling molecules, binding to specific cell surface receptors such as ion channels or G protein-coupled receptors (GPCRs), triggering intracellular reactions. Their outstanding pharmacological profile and intrinsic characteristics make peptides an ideal starting point for the development of new therapies. Notably, peptides demonstrate exceptional safety, tolerability, and efficacy in humans due to their specificity. When compared to protein-based biopharmaceuticals, peptide therapeutics exhibit lower processing complexity, resulting in production costs more akin to small molecules.

Key Market Drivers

Increasing Use in Pharmaceutical Industry

Peptides are highly potent and targeted pharmacological ingredients, exhibiting a diverse range of biological actions. Their broad chemical space, remarkable biological activity, and specificity, coupled with their relative simplicity of synthesis, ready availability, and low toxicity, position peptides as promising candidates for active medicinal components. Peptides can be designed to specifically target certain receptors, enzymes, or proteins in the body, allowing for highly targeted and precise therapeutic interventions. This targeted approach reduces the risk of off-target effects and enhances therapeutic efficacy. Peptides have a wide range of therapeutic applications. They can be used to treat various medical conditions, including cancer, metabolic disorders, cardiovascular diseases, autoimmune disorders, and infectious diseases.

Peptides contribute significantly to the therapeutic landscape, particularly in the fields of oncology, diabetes, and obesity, generating billions of dollars in revenue. Moreover, the demand for peptides is steadily increasing for the treatment of renal failure, rare disorders, as well as cardiovascular and neurological conditions. Currently, there are over 100 peptide-based medications available, and with nearly 700 peptide medicines and therapeutic peptides in preclinical development, this number is projected to grow substantially.

Application of Peptides in Diabetes

The significant market growth can be attributed to the notable increase in the adoption of peptides in the consumer healthcare industries. Peptides have a diverse range of applications in treating various lifestyle disorders, including cancers, diabetes, and obesity. The rising prevalence of these metabolic and lifestyle disorders has opened up opportunities for the utilization of peptide therapeutics in oncology and metabolic disorders. For example, as per the 2021 statistics published by the International Diabetes Federation, there were 537 million adults (20-79 years) living with diabetes worldwide, which accounted for 1 in 10 individuals affected by diabetes. Additionally, the same source reported that 541 million adults had Impaired Glucose Tolerance (IGT), placing them at a high risk of developing type 2 diabetes. Several peptide therapies, such as Glucagon-like peptide-1amide, are known to stimulate insulin secretion postprandially and are widely used in pancreatic therapy. Consequently, the demand for peptide drugs is expected to rise in tandem with the increasing number of diabetic patients, thereby driving the market throughout the forecast.

Focus on New Peptide-Based Treatments

The growing interest in peptides as potential therapeutics and their diverse applications in various fields, such as pharmaceuticals, biotechnology, and diagnostics, has led to increased research activities. Researchers are exploring new peptide-based treatments and developing peptide drugs for a wide range of medical conditions, driving the demand for peptide synthesis. The successful development and approval of new peptide-based drugs have generated enthusiasm in the pharmaceutical industry. As more peptide-based therapies gain regulatory approval, the market for peptide synthesis equipment and services expands to meet the demand for these innovative drugs.

The peptide synthesis market has experienced significant growth, attributed to increased research activities, novel product approvals, and the rise in funding for research and development. Advanced peptide synthesizers have played a crucial role in this growth. Notably, in April 2021, ISSAR Pharma announced the licensing of their peptide-based New Chemical Entities (NCEs), along with pre-investigational new drug (IND) filing and a United States patent. These remarkable developments in peptide drugs are anticipated to drive market demand.

Expanding Applications in Diagnostics and Imaging

Peptide-based biosensors are designed to detect specific biomolecules or analytes in biological samples. These biosensors can be used for early disease detection, monitoring treatment responses, and measuring various biochemical parameters. Peptide sequences with high affinity and selectivity for target molecules are incorporated into the biosensor to ensure accurate and sensitive detection.

Peptides are used to develop imaging agents that can bind to specific disease-related targets in the body. These imaging agents are used in molecular imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Peptide-based imaging agents provide non-invasive and targeted visualization of disease sites, aiding in diagnosis and treatment planning. Peptides play a vital role in diagnostic applications, encompassing the advancement of peptide-based biosensors, imaging agents, and biomarkers. The increasing demand for non-invasive and targeted diagnostic tools, like peptide-based imaging agents for molecular imaging and peptide-based biosensors for disease detection, is propelling market growth.

Download Free Sample Report

Key Market Challenges

Purification and Quality Control

During peptide synthesis, side reactions and formation of by-products can occur, leading to impurities in the final product. Ensuring high purity involves careful optimization of the synthesis conditions to minimize the formation of impurities. Achieving high purity can be resource-intensive, as it may require substantial amounts of reagents, solvents, and specialized equipment. The cost of purification can add to the overall production expenses. Moving from small-scale to large-scale peptide synthesis can present challenges in maintaining consistent purity levels. Factors such as reaction kinetics and mass transfer can differ at larger scales, necessitating additional process optimization. Obtaining peptides of high purity is crucial for their successful application in research and therapeutics. Purification methods, such as high-performance liquid chromatography (HPLC), can be time-consuming and require optimization for each peptide sequence. Quality control measures are essential to ensure the accuracy, consistency, and safety of synthesized peptides. Maintaining high-quality standards and efficient purification processes can be a challenge for the peptide synthesis market.

Regulatory Issues

Peptides are highly sought after for the treatment of cardiovascular and neurological disorders, renal failure, and rare diseases. Currently, there are over 100 FDA-approved peptide-based medications available in the market. The number of peptide medicines in clinical trials or preclinical research has surpassed 700, indicating a significant potential for expansion. These peptide-based medications are classified as both small-molecule and large-molecule biologics. However, their unique position between small molecules and large proteins has posed regulatory challenges. While most of these medications are chemically synthesized, their mechanisms of action vary widely.

Developing a comprehensive set of regulatory rules that adequately address the safety and quality requirements for such a diverse range of molecular entities with distinct modes of action is a complex task. The absence of established regulatory criteria for this class of medications further complicates matters. Moreover, there exists a disagreement between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding the regulatory clearance of peptide-based medications. The FDA classifies peptide medications as small-molecule pharmaceuticals under the authority of the FDA's Center for Drug Evaluation and Research (CDER), whereas the EMA favors a centralized approach over the mutual recognition procedure. This lack of uniform regulatory guidelines has hindered the acquisition of permits for therapeutic peptides, limiting their application areas. Consequently, it serves as a significant barrier to the growth of the global peptide synthesis industry.

Key Market Trends

Increasing Opportunity in Rare Diseases Therapeutics

Peptides can be strategically designed to target specific molecular pathways or genetic mutations associated with rare diseases. This precision-oriented approach allows for more effective and tailored therapeutic interventions. Peptides can be customized to address specific rare mutations or genetic variants, enabling treatments to be tailored to individual patients through personalized medicine approaches. Peptide-based therapies often offer non-invasive delivery options, making them an appealing choice for patients with rare diseases who may have limited tolerance for invasive procedures. Regulatory agencies provide incentives and special designations for drugs developed to treat rare diseases, creating opportunities for companies to pursue research and development in this field.

Peptides offer promising solutions for the treatment of rare genetic disorders and orphan diseases. The expansion of the peptide synthesis market presents an opportunity to develop and manufacture peptide-based therapeutics targeting these conditions. Companies can focus on designing and synthesizing peptides that specifically address molecular targets associated with rare diseases, thus catering to unmet medical needs.

Use of Peptides in the Development of Personalized Medicine

The notion of individualized therapy aimed at achieving the best response and maximizing safety margins to enhance patient care has generated considerable interest in personalized treatment. Proteomic analysis presents itself as an appealing and effective approach for deciphering the molecular profiles of distinct tissues, whether healthy or diseased. The emergence of personalized proteomics or proteomic profiling represents a significant stride forward in understanding disease path mechanisms. Within the framework of the EU-funded ElectroMed project, researchers have proposed the development of a user-friendly platform to facilitate electrochemically guided peptide synthesis. This innovative platform will be based on a microfluidic multiplexing system, controlled by software, thus promoting the broader application of proteomics in personalized medicine.

Additionally, label-free sensors utilizing nanomaterials will be employed to detect and quantify ligand-receptor complexes. This technological advancement will enable the automated injection of various reagents required for ligand synthesis, thereby facilitating personalized and controlled peptide synthesis in the context of personalized treatment. The growing investments in personalized medicine can be largely attributed to the rising prevalence of diseases such as cancer and cardiovascular disease (CVD), along with the increasing demand for treatments with minimal adverse effects. Personalized medicine has the potential to enhance healthcare quality while simultaneously reducing costs. Consequently, players in the peptide synthesis market stand to benefit from these advancements in the field of customized medicine.

Segmental Insights

Technology Insights

Based on Technology, Liquid-Phase Peptide Synthesis (LPPS) has dominated the global market throughout the forecast period, while solid-phase peptide synthesis has shown the fastest growth. The integration of automation and advancements in both liquid and solid-phase peptide synthesis has significantly contributed to cost reduction in peptide synthesis. Consequently, this is expected to drive the adoption of peptide synthesis worldwide, resulting in increased global revenue during the forecast period. Conventional studies suggest that solid-phase peptide synthesis is a suitable approach for GMP manufacturing and API process development due to its cost-effectiveness in synthesizing long peptide sequences (more than 10 amino acids) with smaller volumes. However, it is important to note that purification costs associated with solid-phase peptide synthesis can potentially increase manufacturing costs at any scale of production. On the other hand, liquid-phase peptide synthesis is commonly used for developing shorter peptide sequences and large volumes. In some cases, hybrid approaches are employed for synthesizing long sequences at large volumes.

Regional Insights

Based on Region, North America holds the largest market share in the global peptide synthesis market. This dominance is attributed to well-established pharmaceutical and biotechnology industries, a strong focus on R&D, advanced healthcare infrastructure, and significant investment in drug development initiatives. The region, particularly the United States, continues to be a major hub for innovation in peptide-based therapeutics and diagnostics. A critical factor driving this leadership is the presence of key market players and research institutions conducting cutting-edge work in peptide chemistry and personalized medicine. Moreover, the demand for synthetic peptides in cancer therapy, metabolic diseases, and autoimmune disorders has grown significantly due to a rising geriatric population and increasing chronic disease prevalence.

Recent Developments

• In May 2025, Bachem, a Swiss leader in peptide and oligonucleotide manufacturing, announced significant investments to expand production capacities across its global network. The company is enhancing facilities in Bubendorf, Switzerland; Vista, California; and St Helens, UK, to meet the increasing demand for peptide-based therapeutics.
• In December 2024, Lonza announced a strategic restructuring of its Contract Development and Manufacturing Organization (CDMO) business. The company introduced the “One Lonza” strategy, consolidating its operations into integrated platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. This reorganization aims to streamline operations, enhance customer experience, and support future growth.
• In June 2023, Biotage launched the Biotage PeptiPEC-96, an automated, high-throughput peptide purification system developed in collaboration with Gyros Protein Technologies. This system integrates Gyros' PurePep EasyClean (PEC) catch-and-release technology with the Biotage Extrahera workstation, simultaneously purifying up to 96 peptides. Compared to traditional reversed-phase high-performance liquid chromatography (RP-HPLC), the PeptiPEC-96 offers purification that is 75% faster and reduces solvent consumption by up to 98%. This advancement addresses the bottleneck in peptide synthesis workflows, facilitating more efficient screening and development of peptide-based therapeutics.
• In May 2023, PolyPeptide, a global Contract Development and Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based Active Pharmaceutical Ingredients (APIs), and Numaferm, a biotech company based in Germany with expertise in process development and production of peptides and proteins, have entered into a Preferred Partner Collaboration Agreement for peptide development and production. This collaboration leverages PolyPeptide's cGMP manufacturing capabilities, regulatory knowledge, and market access, along with Numaferm's biochemical production platform and expertise in sustainable peptide manufacturing.
• In June 2023, IRBM, an innovative contract research organization, announced the signing of a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD outside the USA and Canada, to further their collaboration in the field of peptide therapeutics.
• In June 2022, Evonik introduced a novel peptide aimed at enhancing the productivity of cell-culture-based biopharmaceuticals. cQrex AC represents a chemically defined and highly soluble source of L-cystine, facilitating an adequate supply of this pivotal amino acid to cells.
• In May 2022, the United States Food and Drug Administration granted approval for Mounjaro (tirzepatide) injection to enhance blood sugar control in adults with type 2 diabetes, as an adjunct to diet and exercise. Mounjaro belongs to a class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.

Key Market Players

·         PolyPeptide Group

·         Merck KGaA

·         Thermo Fisher Scientific

·         Enamine Ltd.

·         Alfa Chemistry

·         CEM Corporation

·         GenScript

·         AAPPTec

·         Bachem Holding

·         AnaSpec, Inc.

Report Scope:

In this report, the Global Peptide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peptide Synthesis Market, By Product:

o   Equipment

o   Reagents and Consumables

o   Others

• Peptide Synthesis Market, By Technology:

o   Solid-Phase Peptide Synthesis (SPPS)

o   Solution-Phase Synthesis (SPS)

o   Liquid-Phase Peptide Synthesis (LPPS)

• Peptide Synthesis Market, By Application:

o   Therapeutics

o   Diagnosis

o   Research

• Peptide Synthesis Market, By End User:

o   Pharmaceutical and Biotechnology Companies

o   Contract Manufacturing Organization (CMO)

o   Academic and Research Institutes

• Peptide Synthesis Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Synthesis Market.

Available Customizations:

Global Peptide Synthesis market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Peptide Synthesis Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]